The biological behavior of MCT is variable, ranging from solitary benign tumors to a highly invasive and metastatic disease. 4 In order to classify canine MCT, a grading system was developed based on histological findings. 5 system is of prognostic significance concerning survival. [6] [7] [8] However,
regardless of the grade all MCT are considered to be potentially malignant.
The etiology of MCT is largely unknown but probably multifactorial, as evidenced by different aberrations in neoplastic MC. One of the commonly mutated genes described in literature in neoplastic MC is KIT.
4,9
The encoded protein KIT is a tyrosine kinase receptor, which activates various downstream targets including the signal transducer and activator of transcription 5 (STAT5) and plays a major role in MC growth. In many cases, mutations in KIT are associated with ligand-independent activation of the receptor and therefore with autonomous growth of MC. [10] [11] [12] [13] Standard treatment in MCT is surgery with wide excision margins for resectable tumors, chemo-or radiotherapy for non-resectable cases or a combined treatment for residual or locally recurrent MCT. 6, 14 Recently, 2 tyrosine kinase inhibitors (TKI) directed against KIT, namely masitinib and toceranib, have been approved for the treatment of KIT-mutated MCT. [15] [16] [17] [18] These drugs are able to suppress tumor progression in a subset of patients. However, in many cases treatment effects are only temporary. 16, 18 Therefore, current research attempts to identify novel targets and to develop new therapeutic approaches in MCT.
The Janus kinase 2 (JAK2) is a critical, cytoplasmic tyrosine kinase downstream of cytokine (growth factor) receptors, promoting the proliferation of normal and neoplastic cells. JAK2 activates major downstream targets, including STAT5, phosphoinositide 3-kinases (PI3K) and extracellular-signal-regulated kinases (ERK). [19] [20] [21] Recently, the JAK2-targeting drug ruxolitinib has been approved by the FDA for the treatment of human primary myelofibrosis (PMF) and hydroxyurea (HU)-resistant or -intolerant polycythemia vera (PV), in which JAK2-activating mutations are prominent. [22] [23] [24] In 2011, Beurlet et al. identified JAK2 mutations in canine patients suffering from PV. 25 We have recently described that activated STAT5 is constitutively expressed in human neoplastic MC and triggers the proliferation and survival of these cells. 26 Together, JAK2 and STAT5 are considered to be crucial mediators of growth and survival of neoplastic cells and therefore potential therapeutic targets in myeloid neoplasms. 27, 28 However, JAK2 and STAT5 have not been investigated in the context of canine MC neoplasms so far. The aims of this study were to examine the expression and activation of JAK2 and STAT5 in canine MCT and to explore the anti-neoplastic effects of established inhibitors of the JAK2/STAT5 pathway in these cells. For this purpose, 2 established canine MC lines, C2 and NI-1 were used both of which carry several mutations in KIT. 29, 30 In addition, primary neoplastic MC isolated from mastocytoma specimens of different grades according to the Patnaik classification 5 were employed in order to obtain more disease-relevant information about target expression profiles. To evaluate the effects of JAK2-/STAT5 inhibition in MCT, a number of JAK2-or STAT5-targeting drugs were applied. The JAK2-blockers used in this study (R763, TG101348, AZD1480, ruxolitinib) have already been tested in clinical trials and ruxolitinib is even used in clinical practice in human patients with PMF and PV. By contrast, the STAT5-targeting drugs tested (pimozide, piceatannol) have not been applied in clinical oncology so far. We also asked whether JAK2-or STAT5 blockers and KIT-targeting drugs would exert synergistic anti-neoplastic effects in MCT. In summary, the results of our study provide evidence that targeting the JAK2/STAT5 pathway might be a potent approach to tackle otherwise untreatable mastocytoma patients.
| MATERIALS AND METHODS

| Reagents
The compounds used in this study are listed in 
| Isolation of primary canine neoplastic MC from mastocytoma specimens
We isolated neoplastic MC from fresh tumor samples obtained from 3 patients undergoing surgical intervention at the University of Veterinary Medicine Vienna (Vienna, Austria) ( Table 3 ) using collagenase as described. 31 In brief, tissue samples were cut into small pieces, washed thoroughly in Tyrode's buffer and were then incubated in collagenase type 2 (Worthington, Lakewood, New Jersey) at 37 C for 180 minutes.
Isolated MC were recovered by filtration through nytex cloth and collected into FBS-containing tubes. After washing, cells were examined for viability (trypan blue exclusion) and MC numbers.
| Immunohistochemistry and immunocytochemistry
MCT sections were obtained from nine canine patients treated at the University of Veterinary Medicine Vienna (Vienna, Austria) ( 
Sigma-Aldrich
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ASM, aggressive systemic mastocytosis; C max , peak plasma concentration of a drug after administration; CML, chronic myelogenous leukemia; CSF-1, colony stimulating factor 1; DFSP, dermatofibrosarcoma protuberans; EGFR, epidermal growth factor receptor; ET, essential thrombocythemia; FGFR3, fibroblast growth factor receptor 3; FLT3, fms-like tyrosine kinase 3; GIST, gastrointestinal stromal tumor; HES/CES, hypereosinophilic syndrome/chronic eosinophilic leukemia; JAK, janus kinase; LCK, leukocyte C-terminal SRC kinase; LYN, LCK/YES novel tyrosine kinase; MCT, mast cell tumor; MDS/MPD, myelodysplastic/myeloproliferative disease; PDGFR, platelet-derived growth factor receptor; PK, protein kinase; PMF, primary myelofibrosis; PV, polycythemia vera; STAT, signal transducer and activator of transcription; SYK, spleen tyrosine kinase; TYK2, tyrosine kinase 2; VEGFR, vascular endothelial growth factor receptor.
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Range of concentrations used in this study.
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ChemieTek, Indianapolis, Indiana; LC Laboratories, Woburn, Massachusetts; Rigel Pharmaceuticals, San Francisco, California; Sigma-Aldrich, St. Louis, Missouri.
3
PV patients intolerant or resistant to hydroxyurea.
reported. 30 In brief, cells were stained with the Alexa Fluor 647- The specific reactivity of the anti-JAK2 mAb D2E12 and the anti-KIT antibody C-19 for the canine species was previously confirmed by others. 34, 35 To validate the cross-reactivity of antibodies against human pSTAT5, and stained with PI as reported. 31 The amount of DNA-bound PI was then determined using flow cytometry.
| Statistical analysis
To determine the significance in differences between the drug-treated conditions and the untreated control condition in our experiments, the Student's t-test was applied. Results were considered statistically significant when P was < .05. Drug combination effects on apoptosis were evaluated by CompuSyn and considered to be synergistic when the combination index (CI) was < 1, additive when CI = 1 and antagonistic when CI > 1.
3 | RESULTS
| Canine neoplastic MC exhibit activated JAK2, STAT5 and KIT
As determined by immunocytochemistry, C2 cells and NI-1 cells were found to express JAK2, pJAK2, pSTAT5, KIT and pKIT ( Figure 1A ).
The presence of intracellular pSTAT5 and STAT5 as well as surface KIT in C2 and NI-1 cells was also demonstrable using flow cytometry ( Figure 1B ). In these experiments, higher levels of pSTAT5 were detected in C2 cells compared with NI-1 cells whereas STAT5-and KIT levels were comparable in the 2 cell lines. Furthermore, we were able to demonstrate the expression of pSTAT5 in primary MCT by IHC (Table 3 , Figure 1C ). In particular, pSTAT5 was detected in neoplastic MC in 9 of 9 canine patients examined. 
| JAK2-, STAT5-and KIT-targeting drugs counteract STAT5 activation in C2 and NI-1 cells
To evaluate the functional role of JAK2 and STAT5, we treated C2
and NI-1 cells with various targeted drugs. As shown in Figure 2A (left panel) and NI-1 (right panel) cells were exposed to various inhibitors for 4 hours and levels of phosphorylated STAT5 and total STAT5 were examined using Western blotting as described in the text (upper panel). β-Actin served as loading control. The levels of pSTAT5 were quantified by densitometry and normalized to β-Actin (lower panel). Results are expressed relative to control (=1.0) and represent the mean AE SD of 3 independent experiments. *P < 0.05. (Table 4) . When comparing drug effects in primary neoplastic MC with the effects obtained in the 2 cell lines examined no major differences were found ( Figure 3 , Table 4 ).
| JAK2-and STAT5 inhibitors induce apoptosis in canine MC lines
Next, we investigated the mechanism of drug action and asked whether the JAK2-and STAT5-targeting drugs applied would induce apoptosis in canine MC lines. As assessed by Annexin V/PI staining, R763, TG101348, AZD1480, pimozide and piceatannol were found to induce apoptosis in C2 cells and NI-1 cells (Figure 4) . Pimozide, R763 and AZD1480 showed comparable effects in C2 and NI-1 cells whereas piceatannol and TG101348 were found to be more effective in NI-1 cells than in C2 cells. In general, higher concentrations of STAT5 blockers were necessary to induce apoptosis in canine MC lines compared with the JAK2 inhibitors applied.
| JAK2-targeting drugs induce cell cycle arrests in C2 cells and NI-1 cells
To further explore the mechanism of drug-induced inhibition of proliferation in neoplastic MC, we examined the effects of JAK2-and STAT5 inhibitors on cell cycle progression. Interestingly, these drugs were found to exert distinct and variable effects on cell cycle distribution in C2 and NI-1 cells ( Figure 5 ). Whereas R763 induced a G2-phase arrest, TG101348 produced a G1 cell cycle arrest in both cell lines. AZD1480 was found to be effective in C2 cells in inducing an S/G2-phase arrest but did not induce an S/G2 arrest in NI-1 cells. The STAT5 inhibitors tested and the JAK2 inhibitor ruxolitinib showed no effects on cell cycle progression in C2 or NI-1 cells.
| Evaluation of drug combinations in NI-1 cells
To evaluate the effects of drug combinations on apoptosis, NI-1 cells were exposed to various combinations of JAK2-, STAT5-or KIT-targeting drugs. Results were then examined by CompuSyn software to determine synergistic drug combination effects. In these experiments, we identified several drug combinations with synergistic effects regarding induction of apoptosis in NI-1 cells (CI < 1). These drug combinations included "pimozide + toceranib", "pimozide + masitinib", "pimozide + nilotinib", "pimozide + midostaurin", "TG101348 + pimozide" and "TG101348 + toceranib" (Figure 6 ).
| DISCUSSION
MCT are frequently diagnosed skin neoplasms in canines. [1] [2] [3] Although several treatment options including en-bloc resection, radiation, chemotherapy and KIT inhibitors are available, relapses are frequently seen in advanced high-grade MCT patients. 6,14-18 Therefore, new treatment approaches and new targeted drugs are currently being developed. [36] [37] [38] [39] [40] In this study, we have identified the JAK2/STAT5 pathway as a novel potential target for therapy in canine MCT. In particular, several different drugs targeting JAK2 or STAT5 produced growth inhibition and apoptosis in MCT cells. In addition, we were able to show that STAT5 inhibitors and drugs directed against JAK2 or KIT exert potent synergistic anti-neoplastic effects (CI < 1) in canine neoplastic MC. So far, little is known about expression and activation of JAK2 and STAT5 in neoplastic MC. 40 In the human system, neoplastic MC reportedly show nuclear and cytoplasmic pSTAT5. 26, 41 In this study, we were able to demonstrate that canine MCT cells display nuclear and cytoplasmic pSTAT5 independent of the tumor grading. Moreover, we were able to show the presence of pSTAT5 as well as pJAK2 in 2 established canine mastocytoma cell lines, namely C2 and NI-1. To the best of our knowledge, these are the first data suggesting that the JAK2/STAT5 pathway is active in canine neoplastic MC.
The JAK2/STAT5 pathway has recently been implicated in various myeloproliferative neoplasms including PV, where activating JAK2 mutations like JAK2 V617F have been detected in human patients. 24 More recently, this was confirmed in the canine system. 25 Moreover, it has been reported that JAK2 can be recruited and activated by KIT and indeed, SCF-induced colony growth of murine hematopoietic cell lines and human fetal liver cells was found to be reduced after treatment with JAK2 inhibitors. 40, 42 In addition, STAT5 has recently been described as a KITdependent molecular target in human neoplastic MC. [11] [12] [13] In this study,
we were able to show that the KIT-targeting drugs imatinib, masitinib, mid- to reduce the symptom-burden in these patients with a substantial increase in the quality of life. 43, 44 However, in both disease models ruxolitinib exerts effects on the cytokine storm and inflammation rather than on cell proliferation. [43] [44] [45] [46] In this study, we applied a series of drugs known to interact with the activity of JAK2 including ruxolitinib as well as STAT5-targeting drugs. In these experiments, we were able to show that the targeted drugs applied apoptosis in C2 and NI-1 cells was R763. One explanation for the effect of R763 on cell cycle progression may be its inhibitory effect on Aurora kinases. All drugs applied in this study showed effects at a pharmacologically relevant range except for pimozide, piceatannol and ruxolitinib (Table 1) . The 2 STAT5 blockers applied were only effective in inducing apoptosis in canine MC at very high concentrations but not in suppressing cell cycle progression. This observation is consistent with the weak effect of piceatannol in human MC. 26 Unexpectedly, although ruxolitinib was found to decrease expression of pSTAT5 in NI-1 cells and to a lower extent in C2 cells in our flow cytometric experiments, the drug was unable to influence MC survival, cell cycle progression or proliferation of both cell lines at pharmacologically relevant concentrations. These discrepant results may be explained by additional (STAT5-independent) mechanisms of drug resistance in canine MC. Alternatively, the effects of ruxolitinib on STAT5 activation were too weak to lead to a visible growth-inhibitory or anti-survival effect. However, in our Western blot experiments the effect of ruxolitinib on pSTAT5 expression in NI-1 cells was stronger than in our flow cytometric analysis.
Whereas several different effective JAK2 blockers are available, pharmacologic inhibition of STAT5 remains a challenging task mainly because the development of specific STAT5 inhibitors is difficult. [36] [37] [38] [39] In the current study, 2 STAT5 blockers were used, pimozide and piceatannol. However, both drugs are rather weak and non-specific inhibitors of STAT5, which may explain the weak effects on canine neoplastic MC observed in this study.
In contrast to STAT5-targeting drugs, the development of JAK2
blockers is more advanced. The Aurora kinase-and JAK2 blocker R763 has been tested in clinical trials in human hematological malignancies as well as in a dose escalation trial in human patients suffering from solid tumors. 50, 51 The JAK2-targeting drug ruxolitinib has recently been approved by the FDA for treatment of human PMF and HU-resistant or -intolerant PV. 22, 23 One concern with these and other JAK2 blockers is toxicity. Therefore, one general goal is to develop less toxic JAK2 inhibitors. Another option would be to reduce single compound concentrations by applying drug combinations. Indeed, it has been shown that various combinations of kinase blockers can produce synergistic growth-inhibitory effects on canine and human MC. 52, 53 In this study, we were interested to learn whether similar drug combination-effects can be achieved in canine neoplastic MC when combining STAT5-(pimozide), JAK2-(R763, TG101348, AZD1480, ruxolitinib) or KIT inhibitors (imatinib, masitinib, midostaurin, nilotinib, toceranib). In these experiments, the most potent synergistic effects on survival of NI-1 cells were obtained with drug combinations consisting of pimozide and either toceranib, masitinib, nilotinib or midostaurin as well as combinations consisting of TG101348 and pimozide or TG101348 and toceranib (CI < 1).
In summary, we found that canine neoplastic MC express phosphorylated JAK2 as well as STAT5 and that inhibition of the JAK/STAT pathway is associated with decreased proliferation and survival of these cells. Based on our results, we hypothesize that the JAK2/STAT5
pathway is a potential new target in canine MCT. This hypothesis needs to be tested in forthcoming in vivo studies. In case of JAK2 inhibition, the application of novel targeted drugs is a straightforward approach whereas pharmacologic STAT5 blockers are currently being developed and will hopefully enter clinical application in the near future.
